Azenta, Inc. reported a 12% increase in revenue to $161 million for Q3 2026, driven by growth in Sample Management Solutions and Multiomics segments. Adjusted EBITDA improved to $18.5 million with an 11.4% margin, despite a GAAP operating loss due to goodwill impairments and higher expenses. The company completed the sale of B Medical Systems and repurchased $50 million in shares under its ongoing program. For Q4, Azenta expects a slight decline in organic revenue but anticipates adjusted EBITDA between $20 million and $23 million. Full-year revenue guidance was raised slightly to $613-$618 million, with stable organic growth expected.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Applied Materials CEO Gary Dickerson highlighted at the Goldman Sachs conference that AI, especially in data centers, is a major growth driver for the company. The demand for leading-edge wafer fab equipment is surging, with 80% of the growth in 2026...
Kuehn Law is investigating Picard Medical Inc. for possible breaches of fiduciary duty by its officers and directors. The lawsuit alleges that insiders engaged in a fraudulent stock promotion scheme using social media misinformation and fake financia...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
